Brand Name
Elitek
Generic Name
Rasburicase
View Brand Information FDA approval date: July 12, 2002
Form: Kit
What is Elitek (Rasburicase)?
Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. Elitek is a recombinant urate-oxidase indicated for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. Limitations of use: Elitek is indicated only for a single course of treatment. Limitations of Use Elitek is indicated only for a single course of treatment [see Warnings and Precautions.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment